Prostate cancer represents a prevalent malignancy within the male genitourinary system. In recent years, its incidence in China has gradually increased, becoming a significant public health issue. While early detection correlates strongly with improved prognosis, the majority of newly diagnosed prostate cancer patients in China are already in intermediate or advanced stages, precluding curative-intent interventions and contributing to marked survival disparities. The progression of prostate cancer is lengthy, typically encompassing diagnosis, treatment, progression, metastasis, and death, accompanied by a decline in quality of life. Personalized treatment plans should be developed based on the disease stage and patient preferences. In non-metastatic prostate cancer, where the tumor is confined to the prostate, surgery and radiotherapy are the primary treatments, supplemented by neoadjuvant and adjuvant therapies to delay metastasis. For metastatic prostate cancer, systemic therapy is prioritized to prolong survival. In metastatic hormone-sensitive prostate cancer, controlling androgen levels is crucial, while treatment options for metastatic castration resistant prostate cancer are relatively limited, necessitating individualized and precise treatment. During prostate cancer management, prostate-specific antigen levels are closely linked to prognosis and require monitoring. Bone metastasis, the most common site in prostate cancer patients, often triggers skeletal-related events, demanding effective prevention and management. Treatment-related adverse reactions are also a clinical challenge, requiring balanced risk-benefit assessments and judicious drug selection to preserve quality of life. Rapid advancements in screening technologies, surgical innovations, drug development, and China-specific epidemiological factors further complicate decision-making in holistic prostate cancer management. To optimize the standardization of prostate cancer diagnosis and treatment in China, the Genitourinary Oncology Committee of Chinese Anti-cancer Association synthesized global guidelines, clinical evidence and clinical expertise, and addressed critical challenges in the whole-course management of prostate cancer to formulate a multidisciplinary consensus. The expert consensus on whole-course management of prostate cancer (2025 edition) establishes standardized protocols to guide clinical practice, improve treatment outcomes, and enhance patient quality of life.
Humans ; Male ; Prostatic Neoplasms/diagnosis* ; Consensus ; Prostate-Specific Antigen/blood* ; Quality of Life ; Prostatic Neoplasms, Castration-Resistant/pathology* ; China ; Bone Neoplasms/secondary* ; Androgen Antagonists/therapeutic use*

Lung cancer is the malignancy with the highest incidence and mortality burden globally, ranking first in both morbidity and mortality among all types of malignant tumors. Pathologically, lung cancer is classified into non-small cell lung cancer (NSCLC) and small cell lung cancer, with NSCLC accounting for approximately 85% of cases. Due to the often subtle or nonspecific clinical manifestations in early-stage disease, many patients are diagnosed at a locally advanced or metastatic stage, where treatment options are limited and prognosis remains poor. Therefore, molecular targeted therapy focusing on driver genes has become a key strategy to improve the survival outcomes of patients with advanced NSCLC. The epidermal growth factor receptor (EGFR) is one of the most common driver genes in NSCLC. While EGFR mutations occur in approximately 12% of advanced NSCLC patients globally, the incidence rises to 55.9% in Chinese patients. Among EGFR mutations, P-loop and αC-helix compressing (PACC) mutations account for about 12.5%. Currently, EGFR tyrosine kinase inhibitors (TKIs) have become the first-line standard treatment for advanced NSCLC patients with classical EGFR mutations, with efficacy well-established through clinical studies and real-world evidence. However, with rapid advancements in NSCLC precision medicine and deeper exploration of the EGFR mutation spectrum, EGFR PACC mutations have emerged as a key clinical focus. The structural characteristics of these mutations lead to significant variability in responses to EGFR TKIs, leaving therapeutic options still limited, while detection challenges persist due to the sensitivity constraints of current testing technologies, driving increasing demand for improved diagnostic and treatment approaches. The current clinical evidence primarily stems from retrospective analyses and small-scale exploratory studies, while prospective, large-scale, high-level evidence-based medical research specifically targeting this mutation subtype remains notably insufficient. This evidence gap has consequently led to the absence of standardized guidelines or expert consensus regarding optimal treatment strategies for advanced NSCLC with EGFR PACC mutations. As a clinical consensus specifically addressing EGFR PACC-mutant NSCLC, this document provides a comprehensive framework encompassing the clinical rationale for EGFR PACC mutation testing, therapeutic strategies for advanced-stage disease, management of treatment-related adverse events, and follow-up protocols. The consensus underscores the pivotal role of EGFR PACC mutation detection in precision medicine implementation while offering evidence-based recommendations to guide personalized therapeutic decision-making. By establishing clear clinical pathways encompassing molecular testing, therapeutic intervention, and long-term monitoring for EGFR PACC-mutant NSCLC, this consensus aims to meaningfully improve patient survival outcomes while serving as a robust, evidence-based foundation for developing personalized clinical management approaches.
Humans ; Carcinoma, Non-Small-Cell Lung/pathology* ; ErbB Receptors/antagonists & inhibitors* ; Mutation ; Lung Neoplasms/pathology* ; Protein Kinase Inhibitors/therapeutic use* ; Molecular Targeted Therapy ; Consensus

Mutations in the human epidermal growth factor receptor 2 (HER-2) gene are recognized as significant but relatively rare driver alterations in non-small cell lung cancer (NSCLC). These mutations predominantly manifest as gene mutation, amplification, and protein overexpression, with an estimated prevalence from 2.8% to 15.4% among NSCLC patients in China. Research indicates that HER-2 mutations, particularly exon 20 insertions (ex20ins), are strongly correlated with aggressive tumor biology, poor prognosis, and limited responsiveness to immunotherapy, thereby exhibiting characteristics of "cold tumors". Overexpression and amplification of HER-2 are also indicative of a heightened risk of chemotherapy resistance and unfavorable survival outcomes, suggesting a distinct molecular subtype with unique biological behaviors. In recent years, novel antibody-drug conjugates (ADCs), particularly trastuzumab deruxtecan (T-DXd), have demonstrated groundbreaking efficacy in HER-2-mutant advanced NSCLC patients. These ADCs have shown significant clinical benefits, including high objective response rates and progression-free survival advantages, making T-DXd the first targeted therapy approved for this patient population globally. Additionally, ADCs have exhibited therapeutic potential in patients with HER-2 overexpression, thus broadening the scope of their indications. To standardize the clinical diagnosis and treatment of HER-2 variant NSCLC, the Chinese Anti-cancer Association convened multidisciplinary experts from oncology, pulmonology, thoracic surgery, pathology, and molecular diagnostics to develop this consensus based on the latest evidences from both domestic and international studies, coupled with China's clinical practice experience. This consensus focuses on the molecular characteristics, clinical significance, diagnostic strategies, treatment options, and safety management of HER-2 alterations, addressing ten critical clinical questions in a systematic manner. It is recommended that HER-2 status be routinely tested at initial diagnosis, disease progression, or recurrence in NSCLC. Mutation detection should prioritize next-generation sequencing (NGS), while protein overexpression may be assessed using immunohistochemistry (IHC) standards for gastric cancer. Fluorescence in situ hybridization (FISH) is recommended for detecting HER-2 amplification. Regarding treatment, for HER-2-mutant patients, first-line therapy may involve chemotherapy with or without immune checkpoint inhibitors (ICIs), similar to treatment approaches for driver-gene negative populations. Upon failure of first-line treatment, trastuzumab deruxtecan, may be considered as alternative therapeutic options. For patients with HER-2 overexpression, ADCs should be considered after failure of standard systemic therapy. However, the management of HER-2 amplification remains insufficiently supported by evidence, necessitating a cautious, individualized approach. The consensus also includes detailed recommendations for screening and managing adverse effects associated with ADCs, such as interstitial lung disease (ILD), emphasizing the crucial role of safety management in ensuring treatment efficacy. The publication of this consensus aims to drive the standardization of molecular diagnosis and treatment pathways for HER-2 variant NSCLC, improve clinical outcomes and quality of life for patients, and facilitate the implementation of personalized precision treatment strategies.
Humans ; Carcinoma, Non-Small-Cell Lung/pathology* ; Lung Neoplasms/pathology* ; Receptor, ErbB-2/metabolism* ; Mutation ; Immunoconjugates/therapeutic use* ; Consensus ; Trastuzumab/therapeutic use* ; Camptothecin/analogs & derivatives*

Breast cancer is the most common malignant tumor in women worldwide,and its incidence rate is increasing annually.Early dia-gnosis is essential for improving patient prognosis.In recent years,artificial intelligence(AI)technology has emerged as a transformative tool,providing new directions for accurate diagnostic and prognostic assessments.This article systematically reviews research progress in the ap-plication of AI to breast cancer screening,multimodal imaging techniques for diagnosis,pathological diagnosis,treatment,and prognostic modeling.Through machine learning and deep learning algorithms,AI has demonstrated significant advantages in the enhancement of dia-gnostic accuracy,efficiency,and accessibility,including improvement of the detection rate of small lesions,reduction in the radiologists'workload,and optimization of treatment decisions.Despite challenges,including the integration of explainable technology in clinical trans-formation,lack of data standardization,complexity of multimodal data,and risk of model generalization,AI is expected to play a more prom-inent role in the precise diagnosis and intelligent therapy for breast cancer,thereby contributing to the full realization of the goal of preci-sion medicine.

Sentinel lymph node biopsy(SLNB)has become the standard technique for axillary staging in breast cancer,promoting a more in-dividualized approach to axillary surgery.This review discusses several current emerging issues in SLNB for patients with breast cancer:inpa-tients with 1-2 positive sentinel lymph nodes(SLNs),studies such as SENOMAC have reinforced the safety of omitting axillary lymph node dissection(ALND),although careful consideration remains necessary for patients with abnormal axillary imaging findings and in the context of post-operative regional nodal radiotherapy strategies.Omission of SLNB may be appropriate in early-stage patients with clinically and ra-diologically negative axilla under strictly defined conditions to further minimize surgical trauma.In parallel,techniques for SLNB after neoad-juvant therapy continue to advance,with tumor safety outcomes becoming increasingly reliable,and the dual de-escalation of both surgery and radiotherapy may be anticipated.In addition,regional lymph nodes serve not only as the initial site of tumor metastasis but also as crit-ical hubs of the adaptive immune response,positioning SLNs a potential window into tumor immune surveillance.

Hormone receptor positive/human epidermal growth factor receptor 2 negative(HR+/HER2-)breast cancer is the most common breast cancer subtype,accounting for approximately 65%-70%of breast cancers.Endocrine therapy is the cornerstone of adjuvant therapy.Even with standard endocrine therapies,patients may still experience local and/or systemic recurrence.Recently,with the application of cyc-lin-dependent kinase 4/6(CDK4/6)inhibitors,significant breakthroughs and advances have been made in the adjuvant treatment strategies for HR+/HER2-early stage breast cancer.Both the MonarchE and NATALEE studies were phase Ⅲ clinical trials evaluating CDK4/6 inhibitors in combination with endocrine therapy for the adjuvant treatment of HR+/HER2-early stage breast cancer.These two studies confirmed that CDK4/6 inhibitors in combination with endocrine therapy significantly prolonged invasive cancer-free survival(iDFS),providing a new option for the intensive treatment of patients at a high risk of recurrence.Based on this,CDK4/6 inhibitors were first recommended for use in treat-ing high-risk HR+/HER2-early stage breast cancer by the 2025 Committee of the Breast Cancer Society guidelines.Despite its established ef-ficacy,further research is needed to determine the optimal treatment duration,long-term survival benefits,safety management,and cost-effectiveness.In this study,we have systematically reviewed the latest medical evidence of endocrine therapy for HR+/HER2-early stage breast cancer,and discussed the precision treatment strategy,and look forward to future directions such as circulating tumor DNA(ctDNA)dynamic monitoring,treatment"escalation"and"de-escalation,"novel drug combination and post-resistance treatment strategies in the ad-juvant setting to provide scientific reference for clinical treatment.

Breast cancer-related lymphedema(BCRL)is a common and severe complication of axillary lymph node dissection,with its patho-genesis closely linked to the disruption of axillary lymphatic drainage.This article systematically reviews the preventive strategies for BCRL(de-escalation of axillary surgery,non-surgical interventions,and prophylactic microsurgical techniques),along with treatment modalities(non-surgical complex decongestive therapy,lymphatic reconstruction surgery,and debulking procedures).Current clinical controversies and future research directions have also been discussed,by integrating the latest evidence-based medical data,to provide a reference for stand-ardized BCRL management.

Objective:To analyze the screening results of the Urban Cancer Early Diagnosis and Treatment Project in Qinghai Province from 2019 to 2024.Methods:A summary and statistical analysis were conducted on six years of screening data from the Urban Cancer Early Dia-gnosis and Treatment Program in Qinghai Province,with the high-risk rate,screening rate,and detection rate calculated separately for each type of cancer.Results:From 2019 to 2024,56,882 high-risk individuals were identified.The high-risk rates for lung,colorectal,breast,up-per gastrointestinal,and liver cancer were 22.02%,21.57%,14.23%,13.52%,and 6.10%,respectively.Overall,13,592 individuals com-pleted clinical screening,with detection rates of 0.32%for lung cancer,0.41%for liver cancer,0.08%for precancerous gastric lesions,3.63%for precancerous colorectal lesions,0.08%for esophageal cancer,0.16%for gastric cancer,and 0.14%for colorectal cancer.Conclusions:The implementation of the Urban Cancer Early Diagnosis and Treatment Program in Qinghai Province aids in the early detection of cancer,improves early diagnosis and survival rates,and reduces mortality.Nevertheless,due to low public awareness and limited participation,en-hancements in program management and public outreach are required.

With the widespread useof immune checkpoint inhibitors(ICIs)in the treatment of various solid tumors,immune-related adverse events have attracted increasing clinical attention.Although ICI-associated myocarditis is rare,it typically has an insidious onset,progresses rapidly,and carries a high mortality rate,making it one of the most severe complications of ICI therapy.Early recognition and management remain challenging due to the absence of standardized diagnostic and therapeutic guidelines.ICI-associated myocarditis is characterized by the following features,with symptom onset commonly occurring within weeks of initiating ICI therapy.Its clinical manifestations are often non-specific and can be misdiagnosed as coronary artery disease or viral myocarditis.Prompt administration of high-dose corticosteroids combined with immunosuppressants,cardiac rhythm and functional support,is crucial for effective management.Although numerous stud-ies highlight the importance of early detection and multidisciplinary collaboration,there is still no consensus on standardized treatment pro-tocols.This report describes a case of acute ICI-associated myocarditis with ovarian cancer who developed symptoms after receiving com-bined apalutamide and toripalimab therapy.The patient responded well to corticosteroid pulse therapy,second-line immunosuppressants,and intensive care support.Due to recurrent ventricular arrhythmias,an implantable cardioverter defibrillator was placed,and cardiac func-tion remained stable during follow-up.Through this case and a review of the relevant literature,we discuss the clinical features,compre-hensive treatment strategies,and long-term management approaches for ICI-associated myocarditis,aiming to raise clinical awareness,pro-mote standardized multidisciplinary team collaboration,and ultimately improve patient outcomes.

Glioblastoma(GBM)is the most aggressive primary malignant tumor in the central nervous system.GBM frequently recurs after surgery and has limited therapeutic options.Hydrogels,characterized by their injectability,biocompatibility,and controlled drug release,of-fer innovative solutions for postoperative GBM management.Advances in hydrogel technology provide new avenues for personalized GBM treatments with significant clinical potential.This article focuses on the current progress in the research on hydrogels as carriers for chemo-therapeutic drugs,immunomodulatory platforms,and multimodal therapeutic systems.Key strategies,including thermo-and pH-responsive gels,co-delivery systems,and the regulation of macrophage function,are analyzed for their therapeutic efficacy.Additionally,the advant-ages of hydrogels in surgical cavity filling,targeted therapy,and recurrence prevention are highlighted.We also discuss the challenges in clin-ical translation and future directions of hydrogel application in postoperative GBM management.